HCV F1/F2 patients: treat now or continue to wait. (February 2014)

• Record Type: Journal Article
• Authors: Shiffman, Mitchell L.; Benhamou, Yves
• Is Part Of: Liver international. Volume 34(2014)Supplement 1
• Page Start: 79
• Page End: 84
• Publication Date: 2014-02
• Subjects: chronic hepatitis C virus -- faldaprevir -- sofosbuvir -- simeprevir; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.12408
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: The treatment of chronic HCV is evolving rapidly. In 2014, three new oral antiviral agents, simeprevir, faldeprevir and sofosbuvir will become available for patients with HCV genotype 1. These agents have far less side effects than the first generation protease inhibitors telaprevir and boceprevir. Treatment will therefore be easier for patients to tolerate but still require peginterferon and ribavirin (PEGINF/RBV). The first IFN free therapy, sofosbuvir (SOF) and ribavirin (RBV), will also become available in 2014. This treatment is highly effective for patients with HCV genotype 2. However, SVR rates with SOF/RBV appear to be similar to that achieved with PEGINF/RBV in patients with HCV genotype 3. The first IFN‐free all oral antiviral therapy combination for patients with HCV genotype 1 may be available late in 2014 or early 2015. The factors which should be considered when deciding whether to treat a patient with HCV now or to delay treatment until IFN free therapies are available is discussed.